175 related articles for article (PubMed ID: 17896107)
1. The depletion of cellular ATP by AG2034 mediates cell death or cytostasis in a hypoxanthine-dependent manner in human prostate cancer cells.
Obajimi O; Melera PW
Cancer Chemother Pharmacol; 2008 Jul; 62(2):215-26. PubMed ID: 17896107
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of de novo purine synthesis in human prostate cells results in ATP depletion, AMPK activation and induces senescence.
Obajimi O; Keen JC; Melera PW
Prostate; 2009 Aug; 69(11):1206-21. PubMed ID: 19434633
[TBL] [Abstract][Full Text] [Related]
3. An inhibitor of glycinamide ribonucleotide formyltransferase is selectively cytotoxic to cells that lack a functional G1 checkpoint.
Zhang CC; Boritzki TJ; Jackson RC
Cancer Chemother Pharmacol; 1998; 41(3):223-8. PubMed ID: 9443639
[TBL] [Abstract][Full Text] [Related]
4. Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell lines.
Faessel HM; Slocum HK; Rustum YM; Greco WR
Biochem Pharmacol; 1999 Mar; 57(5):567-77. PubMed ID: 9952321
[TBL] [Abstract][Full Text] [Related]
5. AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase.
Boritzki TJ; Barlett CA; Zhang C; Howland EF
Invest New Drugs; 1996; 14(3):295-303. PubMed ID: 8958185
[TBL] [Abstract][Full Text] [Related]
6. Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells.
Faessel HM; Slocum HK; Rustum YM; Greco WR
Int J Oncol; 2003 Aug; 23(2):401-9. PubMed ID: 12851689
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.
McLeod HL; Cassidy J; Powrie RH; Priest DG; Zorbas MA; Synold TW; Shibata S; Spicer D; Bissett D; Pithavala YK; Collier MA; Paradiso LJ; Roberts JD
Clin Cancer Res; 2000 Jul; 6(7):2677-84. PubMed ID: 10914709
[TBL] [Abstract][Full Text] [Related]
8. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
Zhao R; Zhang S; Hanscom M; Chattopadhyay S; Goldman ID
Clin Cancer Res; 2005 Feb; 11(3):1294-301. PubMed ID: 15709201
[TBL] [Abstract][Full Text] [Related]
9. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.
Smith PG; Marshman E; Calvert AH; Newell DR; Curtin NJ
Semin Oncol; 1999 Apr; 26(2 Suppl 6):63-7. PubMed ID: 10598557
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
Smith SG; Lehman NL; Moran RG
Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks.
Roberts JD; Shibata S; Spicer DV; McLeod HL; Tombes MB; Kyle B; Carroll M; Sheedy B; Collier MA; Pithavala YK; Paradiso LJ; Clendeninn NJ
Cancer Chemother Pharmacol; 2000; 45(5):423-7. PubMed ID: 10803927
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase.
Wang L; Desmoulin SK; Cherian C; Polin L; White K; Kushner J; Fulterer A; Chang MH; Mitchell-Ryan S; Stout M; Romero MF; Hou Z; Matherly LH; Gangjee A
J Med Chem; 2011 Oct; 54(20):7150-64. PubMed ID: 21879757
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implications of inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase to ampk activation and antitumor activity.
Mitchell-Ryan S; Wang Y; Raghavan S; Ravindra MP; Hales E; Orr S; Cherian C; Hou Z; Matherly LH; Gangjee A
J Med Chem; 2013 Dec; 56(24):10016-10032. PubMed ID: 24256410
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034.
Bissett D; McLeod HL; Sheedy B; Collier M; Pithavala Y; Paradiso L; Pitsiladis M; Cassidy J
Br J Cancer; 2001 Feb; 84(3):308-12. PubMed ID: 11161393
[TBL] [Abstract][Full Text] [Related]
15. Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro.
Marshman E; Newell DR; Calvert AH; Dickinson AM; Patel HR; Campbell FC; Curtin NJ
Clin Cancer Res; 1998 Nov; 4(11):2895-902. PubMed ID: 9829758
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing.
Wu Y; Sarkissyan M; Mcghee E; Lee S; Vadgama JV
Breast Cancer Res Treat; 2015 Jun; 151(3):529-39. PubMed ID: 25975952
[TBL] [Abstract][Full Text] [Related]
17. Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines.
Lu X; Errington J; Chen VJ; Curtin NJ; Boddy AV; Newell DR
Clin Cancer Res; 2000 Jan; 6(1):271-7. PubMed ID: 10656458
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor beta (ERβ) mediates expression of β-catenin and proliferation in prostate cancer cell line PC-3.
Lombardi AP; Pisolato R; Vicente CM; Lazari MF; Lucas TF; Porto CS
Mol Cell Endocrinol; 2016 Jul; 430():12-24. PubMed ID: 27107935
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.
Liu Y; Zhang C; Zhang H; Li M; Yuan J; Zhang Y; Zhou J; Guo H; Zhao L; Du Y; Wang L; Ren L
Eur J Med Chem; 2015 Mar; 93():142-55. PubMed ID: 25668494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
